ANI Pharmaceuticals, Inc. to Post Q3 2024 Earnings of $0.75 Per Share, Capital One Financial Forecasts (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Equities research analysts at Capital One Financial raised their Q3 2024 earnings estimates for ANI Pharmaceuticals in a research report issued on Thursday, September 19th. Capital One Financial analyst T. Chiang now forecasts that the specialty pharmaceutical company will post earnings of $0.75 per share for the quarter, up from their prior estimate of $0.74. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.50 per share.

Other equities analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Truist Financial reaffirmed a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.80.

ANI Pharmaceuticals Trading Down 2.6 %

NASDAQ:ANIP opened at $58.52 on Monday. The company has a market cap of $1.23 billion, a PE ratio of 36.58 and a beta of 0.71. The business’s 50 day moving average is $60.89 and its two-hundred day moving average is $63.58. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same quarter in the previous year, the firm earned $1.06 EPS. The company’s revenue was up 18.5% on a year-over-year basis.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Texas Permanent School Fund Corp lifted its holdings in ANI Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after acquiring an additional 172 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in ANI Pharmaceuticals by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after buying an additional 200 shares in the last quarter. Arizona State Retirement System lifted its stake in ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after buying an additional 211 shares in the last quarter. Simplicity Wealth LLC lifted its stake in ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 227 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after buying an additional 233 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the transaction, the chief operating officer now owns 635,363 shares in the company, valued at approximately $40,129,527.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the transaction, the chief operating officer now owns 635,363 shares in the company, valued at approximately $40,129,527.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 46,007 shares of company stock valued at $2,911,790. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.